Economic efffeciency of Bisoprolol in the treatment of congestive heart failure in Germany - An analysis on the basis of the CIBIS-II trial;Wirtschaftlichkeit von Bisoprolol in der Behandlung der Herzinsuffizienz in Deutschland: Eine analyse auf der basis der CIBIS-II-Studie

Medizinische Klinik

Volumn 95, Issue 12, 2000, Pages 663-671

  Szucs, Thomas D ^a   Schwenkglenks, Matthias ^a   Paschen, Britta ^b   Follath, Ferenc ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MERCK KGAA   (Germany)

Author keywords

Adrenergic beta antagonists; Bisoprolol; Congestive heart failure; Cost effectiveness analysis; Drug therapy; Medical economics

Indexed keywords

BISOPROLOL; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; TREATMENT OUTCOME;

EID: 0034671175     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002083     Document Type: Article

References (57)

1. Beta-blockers: The new standard of therapy for mild heart failure
2. Heart and stroke facts and statistics
3. Angiotensin converting enzyme (ACE) and heart failure
4. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS)
6. A randomised trial of β-blockade in heart failure. The Cardiac Insufficency Bisoprolol Study (CIBIS)
7. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
8. Effect of vasodilator therapy on mortality in chronic congestive heart failure
9. Cost-effectiveness of carvedilol for heart failure
10. Chronische Herzinsuffizienz. Sozioökonomische Bedeutung in der Bundesrepublik Deutschland
11. Heart failure: A growing public health problem
12. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
13. Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial
14. National hospital discharge survey
15. The cost effectivenes of enalapril in the treatment of chronic heart failure
16. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) MERIT-HF Study Group
17. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases
18. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators
19. Clinical trial of the month. The CIBIS II study
20. How attractive does a new technology have to be to warrant adoption and utilization?
21. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS)
22. A cost-minimization of heart failure therapy with bisoprolol in the French setting: An analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study
23. From cost of illness to cost-effectiveness in heart failure
24. A cost minimisation analysis of cardiac failure treatment in the UK usiug CIBIS trial data. Cardiac Insufficiency Bisoprolol Study
25. The natural history of congestive heart failure: The Framingham study
26. An evaluation of the cost of heart failure to the National Health Service in the UK
27. Trends in hospitalization for heart failure in Scotland 1980-1990
28. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
29. Preventable causative factors leading to hospital admission with decompensated heart failure
30. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
31. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure
32. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myorcardial infarction. Results of the Survival and Ventricular Enlargement Trial
33. Therapy of left ventricular dysfunction: Implications of recent therapeutic trials and future directions for therapy
34. Cardiovascular Disease in the Netherlands, 1975 to 1995: Decline in mortality, but increasing numbers of patients with chronic conditions
35. Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure
36. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction
37. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany
38. Heart failure. A decison analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial
39. for the Panel on Cost Effectiveness in Health and Medicine. Recommendations on reporting cost effectiveness analyses
40. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
41. Die sozioökonomische Evaluation. Einführung in die Methodologie
42. Kosteneffektivität der Cholesterinsenkung in der koronaren Sekundärprävention in der Schweiz: Eine Untersuchung auf der Grundlage der Scandinavian Simvastatin Survival Study (4S-Studie)
43. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
44. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
45. Current controversies with ACE inhibitor treatment in heart failure
46. Differences in drug treatment of chronic heart failure between European countries
47. Kosten-Wirksamkeits-Analyse der Herzinsuffiienz-Therapie mit ACE-Hemmern am Beispiel Enalapril
48. Enalapril: A review of quality-of-life and pharmacoeconomics aspects of its use in heart failure and mild to moderate hypertension
49. Gains in life expectancy from medical interventions - Standardizing data on outcomes
50. Over 20 years' experience of beta-blockade in heart failure